Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire May 10, 2022

Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

GlobeNewswire May 3, 2022

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

GlobeNewswire February 24, 2022

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

GlobeNewswire February 2, 2022

Aclaris Therapeutics Expands Leadership Team

GlobeNewswire February 1, 2022

Aclaris Therapeutics Provides R&D Update

GlobeNewswire January 11, 2022

Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

GlobeNewswire December 27, 2021

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

GlobeNewswire December 3, 2021

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

GlobeNewswire November 18, 2021

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 3, 2021

Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

GlobeNewswire November 2, 2021

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

GlobeNewswire August 27, 2021

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 26, 2021

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

GlobeNewswire August 5, 2021

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

GlobeNewswire July 8, 2021

This Could Massively Disrupt the $24.35 Billion NSAID Market

Press Releases June 25, 2021

Aclaris Announces Pricing of Public Offering of Common Stock

GlobeNewswire June 9, 2021

Aclaris Announces Proposed Public Offering of Common Stock

GlobeNewswire June 8, 2021

Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

GlobeNewswire June 8, 2021

Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

GlobeNewswire May 17, 2021